tbuckley/cabot-search huggingface dataset:
TCT-19 Vascular response to paclitaxiel-eluting nitinol self-expanding stent in superficial femoral artery lesions: Angioscopic findings at 2, 6 and 12 months after implantation
Authors: Toshiro Shinke, Amane Kozuki, Osamu Iida, Takayuki Ishihara, Kan Zen, Masashi Fukunaga, Tetsuo Horimatsu, Ken-ichi Fujii, Junya Shite, Daisuke Terashita, Yoshiro Tsukiyama, Mitsuyoshi Takahara, Masaaki Uematsu, Shinsuke Nanto
Journal: Journal of the American College of Cardiology (2016)
The Global aHUS Registry: Characteristics of 826 Patients with Atypical Hemolytic Uremic Syndrome
Authors: Christoph Licht, Gianluigi Ardissino, Gema Ariceta, David J. Cohen, Christoph Gasteyger, Laurence A. Greenbaum, Masayo Ogawa, Varant Kupelian, Franz Schaefer, Johan Vande Walle, Véronique Frémeaux-Bacchi
Journal: Blood (2015)
A novel fission-independent role of dynamin-related protein 1 in cardiac mitochondrial respiration
Authors: Huiliang Zhang, Pei Wang, Sara Bisetto, Yisang Yoon, Quan Chen, Shey-Shing Sheu, Wang Wang
Journal: Cardiovascular Research (2016)

Mitochondria in adult cardiomyocytes exhibit static morphology and infrequent dynamic changes, despite the high abundance of fission and fusion regulatory proteins in the heart. Previous reports have indicated that fusion proteins may bear functions beyond morphology regulation. Here, we investigated the role of fission protein, dynamin-related protein 1 (DRP1), on mitochondrial respiration regulation in adult cardiomyocytes. By using genetic or pharmacological approaches, we manipulated the activity or protein level of fission and fusion proteins and found they mildly influenced mitochondrial morphology in adult rodent cardiomyocytes, which is in contrast to their significant effect in H9C2 cardiac myoblasts. Intriguingly, inhibiting endogenous DRP1 by dominant-negative DRP1 mutation (K38A), shRNA, or Mdivi-1 suppressed maximal respiration and respiratory control ratio in isolated mitochondria from adult mouse heart or in adult cardiomyocytes from rat. Meanwhile, basal respiration was increased due to increased proton leak. Facilitating mitofusin-mediated fusion by S3 compound, however, failed to inhibit mitochondrial respiration in adult cardiomyocytes. Mechanistically, DRP1 inhibition did not affect the maximal activity of individual respiratory chain complexes or the assembly of supercomplexes. Knocking out cyclophilin D, a regulator of mitochondrial permeability transition pore (mPTP), abolished the effect of DRP1 inhibition on respiration. Finally, DRP1 inhibition decreased transient mPTP-mediated mitochondrial flashes, delayed laser-induced mPTP opening and suppressed mitochondrial reactive oxygen species (ROS). These results uncover a novel non-canonical function of the fission protein, DRP1 in maintaining or positively stimulating mitochondrial respiration, bioenergetics and ROS signalling in adult cardiomyocyte, which is likely independent of morphological changes.
TCT-173 Safety of Very Early (&lt; 3hrs) Routine Percutaneous Coronary Intervention after Fibrinolysis in ST-segment Elevation Myocardial Infarction
Authors: David Larson, Ross Garberich, Daniel Lips, M. Nicholas Burke, Ivan Chavez, Scott Sharkey, Claire Donovan, Timothy Henry
Journal: Journal of the American College of Cardiology (2016)
Ofatumumab Plus Chemotherapy Followed By G-CSF For Mobilization Of Peripheral Blood Stem Cells (PBSC) In Patients With B-Cell Non-Hodgkin’s Lymphomas (NHL)
Authors: Hui Gao, Wei Wei, Martin Korbling, Celina Ledesma, Rosamar Valverde, Alison M Gulbis, Bcop, James M Reuben
Journal: Blood (2013)
TCT-211 Incidence and Impact of Dual Antiplatelet Therapy Cessation on Clinical Outcomes in Patients with Renal Dysfunction: Insights from the PARIS Registry
Authors: Jaya Chandrasekhar, Usman Baber, Samantha Sartori, Rebecca Pinnelas, Timothy Henry, David Moliterno, David Cohen, Giora Weisz, Annapoorna Kini, Jeffrey Bruckel, Stuart Pocock, Philippe Gabriel Steg, Bernhard Witzenbichler, Antonio Colombo, Alaide Chieffo, Ioannis Iakovou, George Dangas, C. Michael Gibson, Thomas Stuckey, Roxana Mehran
Journal: Journal of the American College of Cardiology (2016)
Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis
Authors: Xiaobo Wang, Ze Zheng, Jorge Matias Caviglia, Kathleen E. Corey, Tina M. Herfel, Bishuang Cai, Ricard Masia, Raymond T. Chung, Jay H. Lefkowitch, Robert F. Schwabe, Ira Tabas
Journal: Cell Metabolism (2016)
P0078 : Laparoscopic radiofrequency ablation versus hepatic resection in the treatment of very early hepatocellular carcinoma in cirrhotic carcinoma: A cohort study
Authors: M. Costa, R. Santambrogio, S. Bruno, M. Kluger, J. Salceda, A. Belli, A. Laurent, M. Barabino, E. Opocher, D. Azoulay, D. Cherqui
Journal: Journal of Hepatology (2015)
TCT-557 Impact of the Extent of Circumferential Plaque on Non-Culprit Lesion-Related Events: A PROSPECT Substudy
Authors: Kohei Koyama, Gary Mintz, Bjorn Redfors, Patrick Serruys, Bernard De Bruyne, Gregg Stone, Akiko Maehara
Journal: Journal of the American College of Cardiology (2016)
IMGN529, a Novel Antibody-Drug Conjugate (ADC) Targeting CD37 Shows Synergistic Activity with Rituximab in Non-Hodgkin Lymphoma (NHL) Models
Authors: Jutta Deckert, Callum M Sloss, Katie O'Callaghan, Jenny Tsui, Nemisha Dawra, Yong Yi, Jennifer A Coccia, Leanne Lanieri, Sharon Chicklas, Angela Romanelli
Journal: Blood (2015)
Use of experimental therapy outside of clinical trials among U.S. oncologists
Authors: J. Peppercorn, S. Joffe, H. J. Burstein, E. Winer
Journal: Journal of Clinical Oncology (2006)

6047 Background: Investigational cancer therapies being tested in clinical trials may be available outside of trials, or “off-protocol” (OPRx). There are no published data on either the frequency of OPRx or the attitudes of physicians towards OPRx. Methods: In spring 2005, we surveyed a random sample of American medical oncologists chosen from the ASCO directory regarding their attitudes and practices surrounding OPRx. We evaluated the correlation between demographic factors, attitudes, use of OPRx, and response to hypothetical cases. All statistical tests were two-sided. Results: 146 of 471 (31%) oncologists responded. 93% reported ever discussing OPRx and 81% ever prescribing OPRx. 66% reported prescribing OPRx ≥ once/year and 12% ≥ once/month. 68% reported denying requests for OPRx ≥ once/year and 6% ≥ once/month. Academic oncologists were simultaneously more likely than community oncologists to have ever provided OPRx (89% v. 75%, p = 0.06 by Fisher’s exact test), to discuss OPRx ≥ 1 month (45% v. 12%, p = .003), and to deny requests for OPRx ≥ 1 month (15% v. 2%, p = 0.02). While 61% of oncologists believe that patients should be discouraged from OPRx, only 31% felt it should not be available. 53% felt that patients considering trial enrollment should be informed if OPRx is available, whereas 34% disagreed. 26% felt that patients considering enrollment have a right to OPRx, whereas 56% disagreed. Neither practice setting nor other demographic factors predicted attitudes towards OPRx. For hypothetical cases, there was little consensus regarding when to prescribe OPRx. For example, prior to the release of data from recent trials, 41% reported that they would prescribe adjuvant trastuzumab OPRx at a patient’s request. Factors correlating with willingness to provide OPRx included non-academic practice setting (p = 0.04), &gt; 15 years in practice (p = 0.08), belief that non-trial care and trial care are equivalent (p = 0.01) and belief that patients have a right to OPRx (p = 0.004). Conclusion: American oncologists commonly discuss and provide OPRx. Attitudes towards and utilization of OPRx vary substantially in the oncology community. Further discussion of OPRx and guideline development appear warranted. No significant financial relationships to disclose.
TCT-483 Angiographic and two-year clinical outcomes following percutaneous coronary intervention for in-stent restenosis of polymer-free sirolimus- and probucol-eluting stent compared with durable polymer zotarolimus-eluting stent
Authors: Yukinori Harada, Roisin Colleran, Sebastian Kufner, Daniele Giacoppo, Tobias Rheude, Jonathan Michel, Jens Wiebe, Salvatore Cassese, Tareq Ibrahim, Karl-Ludwig Laugwitz, Adnan Kastrati, Robert Byrne
Journal: Journal of the American College of Cardiology (2016)
The FcγRllla Polymorphism Correlates with Chronic Graft-Versus-Host Disease and Treatment Related Mortality.
Authors: Akiyoshi Takami, J. Luis Espinoza, Ken Ishiyama, Satomi Ohyachi, Yuki Kato, Yoshimi Kawamura, Yukio Kondo, Shizuka Yasue, Shigeki Ohtake, Shinji Nakao
Journal: Blood (2008)
P3.02a-001 Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK+ NSCLC
Authors: Leora Horn, Heather Wakelee, Karen Reckamp, George Blumenschein, Jeffrey Infante, Corey Carter, Saiama Waqar, Joel Neal, Jon Gockerman, Kimberly Harrow, Gary Dukart, Chris Liang, James Gibbons, Jennifer Hernandez, Tera Newman-Eerkes, Lee Lim, Christine Lovly
Journal: Journal of Thoracic Oncology (2017)
High-Throughput Amplification and Detection of Human Erythrocyte Antigen (HEA) Nucleotide Polymorphisms From Leukocyte Reduced Red Blood Cell (RBC) Units: Implications for Minor RBC Antigen Inventory Management by Hospital Transfusion Services
Authors: Cassandra Josephson, John Roback, Robert Myers, Lisa Hallock, Irene DeMezzo, Christopher Tanzi, Adelbert James, Courtney K Hopkins, Sheilagh Barclay, Ermelina Enriquez, X. Lin, Ghazala Hashmi
Journal: Blood (2010)
TCT-335 Impact of Age on Sex-Based Differences on Cardiovascular Risk Between Men and Women Undergoing PCI: Results from a Large Single-Center Registry with Over 18,000 Patients
Authors: Claire Eden, Usman Baber, Jason Kovacic, Pedro Moreno, Srushti Shah, Pooja Vijay, Nitin Barman, Joseph Sweeny, Prakash Krishnan, George Dangas, Annapoorna Kini, Roxana Mehran, Samin Sharma
Journal: Journal of the American College of Cardiology (2016)
How Hand Osteoarthritis, Comorbidity, and Pain Interact to Determine Functional Limitation in Older People: Observations From the European Project on OSteoArthritis Study
Authors: Paola Siviero, Sabina Zambon, Federica Limongi, Maria Victoria Castell, Cyrus Cooper, Dorly J. H. Deeg, Michael D. Denkinger, Elaine M. Dennison, Mark H. Edwards, Antonella Gesmundo, Ángel Otero, Nancy L. Pedersen, Richard Peter, Rocio Queipo, Erik J. Timmermans, Natasja M. van Schoor, Stefania Maggi
Journal: Arthritis & Rheumatology (2016)

To examine the role of comorbidity and pain in the associations of hand osteoarthritis (OA) with self-reported and performance-based physical function in a general population of elderly persons.We studied data from 2,942 participants ages 65-85 years in the European Project on OSteoArthritis, a collaborative observational study of 6 European cohorts (from Germany, Italy, The Netherlands, Spain, Sweden, and the UK). Outcome measures included self-reported physical function of the hands measured by the AUStralian/CANadian Osteoarthritis Hand Index (AUSCAN) for hand OA physical function subscale and performance-based grip strength measured using a strain gauge dynamometer.Comorbidity was not a confounder in the association of hand OA with self-reported and performance-based functional limitations, while the role of pain as a mediator was confirmed. Anxiety, depression, stroke, and osteoporosis were associated with AUSCAN scores reflecting more impairment. Depression and osteoporosis were associated with less grip strength.Although comorbidity was decidedly and independently associated with hand functional limitation, it had no effect on the relationship of hand OA with physical function. Hand OA was found to be associated with both self-reported and performance-based physical function impairment; the association was found to be partially mediated by pain, which reduced its impact.
Priming with Granulocyte-Colony Stimulating Factor Did Not Improve Outcome in a Randomized Study of Elderly Acute Myeloid Leukemia but Increased Induction Mortality.
Authors: Gesine Bug, Steffen Koschmieder, Juergen Krauter, Stefanie Wiebe, Carla Hannig, Wolf-Karsten Hofmann, Stefan A. Klein, Caroline Zander, Wolfgang Heit, Arnold Ganser, Dieter Hoelzer, Oliver G. Ottmann
Journal: Blood (2006)
RESULTADOS DE LA RESECCIÓN ENDOSCÓPICA MUCOSA EN LESIONES COLORRECTALES DE GRAN TAMAÑO: RESULTADOS DEL ESTUDIO MULTICÉNTRICO ESPAÑOL
Authors: D Martínez-Ares, E Albéniz-Arbizu, M Fraile González, C Guarner Argente, R Pardeiro Pértega, MA Alvarez, J Cobián, Ó Nogales Rincón, CJ Gargallo Puyuelo, JG Martínez Cara
Journal: Endoscopy (2016)

La resección endoscópica mucosa (RME) de las lesiones colorrectales de gran tamaño, apoyada en un correcto diagnóstico endoscópico es una técnica segura y eficaz.
Heme drives hemolysis-induced susceptibility to infection via disruption of phagocyte functions
Authors: Rui Martins, Julia Maier, Anna-Dorothea Gorki, Kilian V M Huber, Omar Sharif, Philipp Starkl, Simona Saluzzo, Federica Quattrone, Riem Gawish, Karin Lakovits, Michael C Aichinger, Branka Radic-Sarikas, Charles-Hugues Lardeau, Anastasiya Hladik, Ana Korosec, Markus Brown, Kari Vaahtomeri, Michelle Duggan, Dontscho Kerjaschki, Harald Esterbauer, Jacques Colinge, Stephanie C Eisenbarth, Thomas Decker, Keiryn L Bennett, Stefan Kubicek, Michael Sixt, Giulio Superti-Furga, Sylvia Knapp
Journal: Nature Immunology (2016)
Leukapheresis Reduces 4-Week Mortality in Leukemia Patient with Hyperleukocytosis-a Retrospective Study from a Tertiary Center
Authors: Nan Xinyu, Srivastava Pallavi, Mamta Puppala, Sai Ravi Pingali, Ibrahim Ibrahim, Lawrence Rice, Alexandria T. Phan, Swaminathan Padmanabhan Iyer
Journal: Blood (2015)
Lack of investment is putting new care models at risk, think tank warns
Authors: Gareth Iacobucci
Journal: BMJ (2016)

A lack of investment is putting the NHS’s plans for new models of healthcare delivery in England at risk, a new report from The King’s Fund has warned.

The report said that £1.8bn (€2bn; $2.2bn) of the £2.1bn allocated to the NHS this year to transform services had been used to plug deficits among NHS acute providers, leaving just £300m to invest in new services.1

NHS England recently announced that £1.8bn would also be set aside to cover deficits in 2017-18 and 2018-19, and the report warned that the …
TCT-83 Transcatheter Aortic Valve Replacement with Different Valve Designs for Elliptic Aortic Annulus Shape
Authors: Yoshio Maeno, Yigal Abramowitz, Hiroyuki Kawamori, YOSHIO KAZUNO, Geeteshwar Mangat, Mohammad Kashif, Tarun Chakravarty, Mamoo Nakamura, Wen Cheng, Raj Makkar, Hasan Jilaihawi
Journal: Journal of the American College of Cardiology (2016)
Analysis of GTV artifacts in all phases of four dimensional CT for peripheral lung cancer based on three-dimensional CT assisted with active breathing control.
Authors: Huanpeng Qi, Jianbin Li, Yingjie Zhang, Qian Shao
Journal: Journal of Clinical Oncology (2012)

e13524 Background: To analysis artifacts of the gross tumor volume (GTV) and correlated affecting factors in all phases of four dimensional CT (4DCT) for peripheral lung cancer based on three dimensional CT (3DCT) assisted with active breathing control. Methods: After respiratory trainning sufficiently, nineteen patients with peripheral lung cancer underwent 3DCT (CT FB ) and 4DCT simulation scans during free breathing and underwent 3DCT simulation scans in end inspiration hold (CT EIH ) and end expiration hold (CT EEH ) assisted with active breathing control. By comparing GTV EIH and GTV EEH , to choose the reference GTV (GTV ref ) used to calculate artifacts of GTV in all phases of 4DCT. To calculate delineation error based on re-delineating GTV in one phase of 4DCT , to calculate the relative deviations (Dev ref ) between the size of GTV delineated based on CT FB (GTV FB ) and GTV ref and between the size of GTV delineated based on all phases of 4DCT , and GTV ref respectively, and to determine the cutoff of GTV size according to the relevance of the maximum relative deviation (Dev max ) and the delineation error when artifacts occurred. Results: GTV EIH was chosen as the GTV ref , the delineation error was 10.2%, for 15 of 19 patients Dev max was larger than delineation error (Z=-2.938, p=0.003). Dev max was larger than delineation error when the mean GTV size was not larger than 6.355 cm 3 . A significant negative correlation was found between GTV EIH and CV GTV (r=-0.68, p=0.002) and between GTV EIH and Dev max (r=-0.691, p=0.001). The maximum median Dev ref of GTV size was GTV FB with 17.83% (-16.10~105.88%); The maximum one throughout the 4DCT was GTV 30 with 17.20% (-6.64~102.05%) and the minimum one was GTV 80 with 4.14% (-18.18~132.53%). The Dev ref of the size of GTV FB (r=0.520, p=0.022), GTV 20 (r=0.545, p=0.016), GTV 30 (r=0.617, p=0.005), GTV 70 (r=0.542, p=0.017), GTV 80 (r=0.576, p=0.01) and GTV 90 (r=0.478, p=0.039). Conclusions: The GTVs in each phase of 4DCT for the peripheral lung cancer all had artifacts,the sizes of the artifacts in 30% and 60% phases were larger, the other were relatively smaller. The size of artifacts correlated significantly with the tumor motion in the CC direction.
TCT-622 Efficay and safety of left atrial appendage closure with three different devices: peri-procedural and mid-term outcomes from a in a “real world” registry
Authors: Jacopo Andrea Oreglia, Paolo Danna, Alberto Pernigotti, Vincenzo Vizzi, Maurizio Di Biasi, Alessandro Colombo, Alberto Barosi, Simone Colombo, Gaia Telli, Maurizio Viecca
Journal: Journal of the American College of Cardiology (2016)
Clinical Analysis Of 120 Cases Of Natural Killer/T Cell Lymphoma, Nasal Type By Single Hospital In The North-Western China
Authors: Rong Liang, Xie qun Chen, Zhe Wang, Bai qin Xian, qin-Guo guo Yan, Lan Yang, Lan Yang, Tao Zhang, Hong tao Gu, bao-Xia xia Dong, Guang xun Gao, Guang xun Gao, mi-Mi mi Shu, Liang Zhang
Journal: Blood (2013)
Sniffing out cancer from real breath samples by means of nanomaterial-based electronic nose device
Authors: R. V. Abdah-Bortnyak, H. Haick, S. Billan, G. Peng, E. Trock, N. Shachada, A. Kuten
Journal: Journal of Clinical Oncology (2009)

e17552 Background: Several studies have shown that characteristic patterns of volatile organic compounds (VOCs) appear to be elevated in the alveolar breath of cancer patients, as compared to healthy controls. It has been shown, that VOCs’ composition acts as a fingerprint for the distinction of a certain cancer from other cancers, including the cases where various cancers have similar type of biomarkers. The goal of the current study is to establish a background to ultimately achieve a simple-to-use device that can detect such patterns of cancer when exhaling into it. Methods: Breath samples were collected from 40 healthy volunteers and 75 patients having known conditions in six main categories: (I) 40 healthy controls; (II) 30 patients with lung cancer; (III) 15 patients with breast cancer; (IV) 20 patients with colon cancer; (V) 5 patients with prostate cancer; and (VI) 5 patients with head and neck cancer. The breath of the volunteers was examined by means of gas chromatography linked with mass spectrometry technique (GC-MS) as well as by an electronic nose device that is based on molecularly modified Au nanoparticles to check the feasibility of the electronic nose in cancer detection via breath samples Results: GC-MS results showed that each category of cancer has a unique pattern (or mixture) of VOCs. In parallel to these findings, results indicate the ability of nanomaterial-based electronic nose devices to differentiate between “healthy” and “cancerous” breath, and, furthermore, between the breath of patients with different cancer types, with &gt;92% sensitivity. Conclusions: The electronic nose technology has a high potential for assessing various types of cancer via simple exhalation procedure. The results provide a launching pad towards obtaining an inexpensive, compact tool that is amenable to widespread screening and that has a potential for direct and real-time monitoring (2–3 minutes only). No significant financial relationships to disclose.
Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2–Positive Metastatic Bladder Cancer
Authors: Thomas Powles, Robert A. Huddart, Tony Elliott, Shah-Jalal Sarker, Charlotte Ackerman, Robert Jones, Syed Hussain, Simon Crabb, Satinder Jagdev, John Chester, Serena Hilman, Mark Beresford, Graham Macdonald, Sundar Santhanam, John A. Frew, Andrew Stockdale, Simon Hughes, Daniel Berney, Simon Chowdhury
Journal: Journal of Clinical Oncology (2017)

Purpose To establish whether maintenance lapatinib after first-line chemotherapy is beneficial in human epidermal growth factor receptor (HER) 1/HER2–positive metastatic urothelial bladder cancer (UBC). Methods Patients with metastatic UBC were screened centrally for HER1/HER2 overexpression. Patients who screened positive for HER1/2 and who did not have progressive disease during chemotherapy (four to eight cycles) were randomly assigned one to one to lapatinib or placebo after completion of first-line/initial chemotherapy for metastatic disease. The primary end point was progression-free survival (PFS). Results Between 2007 and 2013, 446 patients with UBC were screened, and 232 with HER1- or HER2-positive disease were randomly assigned. The median PFS for lapatinib and placebo was 4.5 (95% CI, 2.8 to 5.4) and 5.1 (95% CI, 3.0 to 5.8) months, respectively (hazard ratio, 1.07; 95% CI, 0.81 to 1.43; P = .63). The overall survival for lapatinib and placebo was 12.6 (95% CI, 9.0 to 16.2) and 12.0 (95% CI, 10.5 to 14.9) months, respectively (hazard ratio, 0.96; 95% CI, 0.70 to 1.31; P = .80). Discontinuation due to adverse events were similar in both arms (6% lapatinib and 5% placebo). The rate of grade 3 to 4 adverse events for lapatinib and placebo was 8.6% versus 8.1% ( P = .82). Preplanned subset analysis of patients strongly positive for HER1/HER2 (3+ on immunohistochemistry; n = 111), patients positive for only HER1 (n = 102), and patients positive for only HER2 (n = 42) showed no significant benefit with lapatinib in terms of PFS and overall survival ( P &gt; .05 for each). Conclusion This trial did not find significant improvements in outcome by the addition of maintenance lapatinib to standard of care.
TCT-506 Coronary sinus reduction improves myocardial perfusion reserve index assessed by dipyridamole stress cardiac magnetic resonance.
Authors: Francesco Giannini, Andrea Aurelio, Antonio Esposito, Anna Palmisano, Richard Jabbour, Damiano Regazzoli, Roberto Spoladore, Massimo Slavich, Annarita Botta, Alessia Faccini, Marco Ancona, Antonio Mangieri, Matteo Montorfano, Azeem Latib, Alaide Chieffo, Francesco De Cobelli, Antonio Colombo
Journal: Journal of the American College of Cardiology (2016)
TCT-449 Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent versus Cobalt-Chromium Everolimus-Eluting Stent in De Novo Native Coronary Lesions: The Final 5-Year Results of the TARGET I Randomized Controlled Trial
Authors: Bo Xu, Changdong Guan, Yuejin Yang, Yaling Han, Shao-Liang Chen, Alexandra Lansky, Martin Leon, Runlin Gao
Journal: Journal of the American College of Cardiology (2016)
ESTUDIO PROSPECTIVO RANDOMIZADO CIEGO COMPARANDO AGUJA ESTÁNDAR FRENTE A AGUJA HISTOLÓGICA SHARKCORE EN USE-PAAF DE LESIONES PANCREÁTICAS
Authors: JR Aparicio Tormo, B Martínez Moreno, J Seguí, J Martínez Sempere, F Ruiz, L Compañy, JA Casellas Valdé
Journal: Endoscopy (2016)

La USE-PAAF es el método estándar para obtener muestras del páncreas. La citología es insuficiente en algunos casos. Recientemente ha aparecido un nuevo tipo de aguja histológica.